Edwards Declares Victory In Transcatheter Mitral Valve Contract Suit
This article was originally published in The Gray Sheet
Executive Summary
A jury recommended a $70m award to Edwards Lifesciences unit CardiAQ based on findings that another firm, Neovasc, breached a supplier contract and used CardiAQ's trade secrets to develop a competing transcatheter mitral valve device.